H.C. Wainwright maintains Buy on Cytokinetics stock, $120 target

Tuesday, H.C. Wainwright reaffirmed a Buy rating and a $120.00 price target on Cytokinetics (NASDAQ:CYTK) shares. The stock, currently trading at $37.93, has seen challenging times with a -42.78% return over the past year. According to InvestingPro data, analyst consensus remains strongly bullish with price targets ranging from $47 to $120, suggesting significant upside potential. The firm’s analysts highlighted the recent label updates for Camzyos (mavacamten) as a positive development for obstructive hypertrophic cardiomyopathy (oHCM) patients and healthcare providers, potentially leading to increased growth and adoption of cardiomyopathy inhibitors (CMIs), including aficamten. While InvestingPro data shows Cytokinetics currently operates with moderate debt levels and maintains strong liquidity with a current ratio of 6.17, the company faces near-term profitability challenges.

Last week, Bristol-Myers Squibb (NYSE:BMY), which is not rated by H.C. Wainwright, announced changes approved by the FDA to the Camzyos label, including a reduction in the frequency of required echocardiogram monitoring for certain eligible patients during the maintenance phase to once every six months. The original label stipulated monitoring every 12 weeks. Additionally, the update expanded patient eligibility by removing previous contraindications for use with moderate CYP2C19 inhibitors and strong CYP3A4 inhibitors.

Despite these label changes, the analysts noted that Camzyos still carries a Black Box Warning due to the risk of heart failure resulting from systolic dysfunction. Patients are required to undergo echocardiogram assessments of left ventricular ejection fraction (LVEF) at specified intervals before and during treatment. The medication is also only available through the Camzyos Risk Evaluation and Mitigation Strategy (REMS) program, which imposes restrictions due to contraindicated use with strong CYP2C19 inhibitors and moderate to strong CYP2C19 or CYP3A4 inducers.

H.C. Wainwright’s analysts believe that the label updates simplify treatment protocols and provide greater prescribing flexibility for Camzyos. In their view, these modifications could favorably impact the uptake of CMIs, including aficamten, which is being developed by Cytokinetics. The firm reiterated their Buy rating and $120 price target for Cytokinetics stock, expressing a positive outlook on the company’s prospects. Despite impressive revenue growth of 145.34% in the last twelve months, InvestingPro analysis suggests the stock is currently overvalued, with 8 additional ProTips and a comprehensive Pro Research Report available for deeper insight into the company’s financial health and market position.

In other recent news, Cytokinetics has been in the spotlight with several updates impacting its stock ratings and market outlook. H.C. Wainwright reiterated a Buy rating with a $120 price target, expressing optimism for Cytokinetics’ aficamten, particularly in light of updates to a competitor’s heart drug, Camzyos, by Bristol-Myers Squibb. Meanwhile, Stifel also maintained a Buy rating and an $87 price target, citing the relaxed FDA regulations on Camzyos as a positive indicator for the cardiomyopathy market, which could benefit aficamten. However, BofA Securities adjusted its price target for Cytokinetics to $54, maintaining a Neutral rating due to concerns over the implications of Bristol-Myers’ failed Phase 3 trial of mavacamten for non-obstructive hypertrophic cardiomyopathy (nHCM).

JMP Securities, on the other hand, reaffirmed a Market Outperform rating with a $78 price target, showing confidence in aficamten’s potential, despite the trial setbacks faced by Bristol-Myers. The analysts at JMP emphasized aficamten’s distinct profile and promising Phase 2 results as reasons for their optimism. Citi analyst David Lebowitz noted potential overhang concerns for Cytokinetics’ aficamten due to the trial failure of Bristol-Myers but highlighted differences in trial designs that could favor Cytokinetics’ outcomes. As Cytokinetics continues with its Phase 3 trial for aficamten, investors are closely monitoring these developments, which could significantly impact the company’s positioning in the cardiomyopathy treatment market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.